NUS - NYSE
Nu Skin Enterprises, Inc.
$5.28
-5.7%Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
At a Glance
Live SnapshotNu Skin Enterprises, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Nu Skin Enterprises, Inc. Cash Flow Statement
NUS • NYSE
| Nu Skin Enterprises, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
160.2M | -146.6M | 8.6M | 104.8M | 147.3M | 191.4M | 173.6M | 121.9M | 129.4M | 143.1M | 133M | 189.2M | 364.9M | 221.6M | 153.3M | 136.1M | 89.8M | 65.3M | 43.9M | 32.8M | |
52.3M | 69.8M | 70.9M | 72.5M | 76.3M | 74M | 76.7M | 83M | 71.6M | 72.4M | 71.4M | 54.9M | 34.9M | 33.4M | 32.9M | 29.6M | 28.6M | 30.4M | 33M | 29.1M | |
20K | -55.5M | -18.1M | -51.6M | 5.8M | -11.9M | 2M | -14.9M | 39.2M | -17.7M | 17.4M | 10.4M | -41.7M | 4.7M | 108K | -13.7M | 12.4M | 1.8B | 1.8M | 1.8M | |
24.1M | 14.8M | 15.6M | 12.4M | 23.2M | 24.1M | 9.9M | 26.6M | 19.3M | 8.9M | 7.4M | 17.5M | 32.6M | 21.4M | 15.5M | 10.8M | 10M | 7.3M | 9.3M | 9.3M | |
-86.7M | 257.5M | 123.2M | 62.7M | 82.6M | 49.1M | 48.3M | 58.1M | -4.1M | 40.2M | 27.2M | 53.8M | -1.1M | -3.9M | 36.9M | 3.7M | -2M | -1.8B | -3M | 17.1M | |
-69.6M | -28.3M | -81.7M | -92.7M | -193.6M | 52.6M | -132.4M | -71.9M | 47.1M | 28.3M | 65.7M | -382.3M | 140.6M | 33.7M | -14.3M | 21.4M | -4.8M | -18.1M | -36.3M | -14.4M | |
80.3M | 111.7M | 118.6M | 108.1M | 141.6M | 379.1M | 177.9M | 202.7M | 302.6M | 275.3M | 322.1M | -56.5M | 530.2M | 311M | 224.3M | 187.9M | 133.9M | 103.3M | 48.7M | 75.8M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-34.3M | -41.6M | -58.5M | -59.1M | -68.6M | -63.8M | -66.1M | -70.4M | -60.2M | -50.2M | -56.6M | -101.5M | -185.1M | -96.6M | -41.8M | -53.8M | -20.2M | -16M | -22.7M | -37.7M | |
(0.0) | (0.0) | -77.3M | (8M) | -19M | -14.9M | -8.1M | -38.5M | -31.7M | -8.7M | (0.0) | (0.0) | (12.6M) | -12.6M | -11.7M | (0.0) | (0.0) | (0.0) | (2M) | (2M) | |
(0.0) | -14.8M | -16.9M | -14M | -16.2M | -14.7M | -8.4M | -11.4M | -11.3M | -17.1M | -15.8M | -17.5M | -21.7M | -15.7M | -24.4M | (0.0) | -13.9M | -13.9M | -136.8M | -173.9M | |
10.2M | 18.4M | 18.1M | 5.9M | 15.1M | 14M | 11.2M | 11.5M | 11.3M | 18.1M | 11.5M | 27.3M | 13.1M | 20.1M | 6.6M | 0.0 | 19.1M | 19.1M | 131.5M | 173.9M | |
194.7M | 0.0 | 0.0 | -8M | 0.0 | 0.0 | 0.0 | 116K | -63K | 1.1M | -4.2M | 9.8M | -12.6M | -8.2M | -11.7M | 0.0 | -5.2M | 0.0 | -2M | -2M | |
(170.7M) | -38M | -134.5M | -67.1M | -88.7M | -79.4M | -71.4M | -108.8M | -92M | -57.9M | -60.8M | -91.7M | -193.7M | -104.9M | -71.2M | -53.8M | -20.2M | -10.8M | -28M | -37.7M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-22M | -2.1M | -8.5M | -70M | -80.4M | -144.3M | -825K | -69.6M | -71.7M | -247.2M | -164.1M | -48.1M | -140.9M | -201.5M | -67.1M | -58.5M | -21.1M | -6.1M | -71.1M | -62.1M | |
-170M | -112.9M | 96.8M | 25.6M | 38.1M | -28.2M | -69.5M | 29.9M | -36.2M | 177.6M | 709K | 82.4M | 11.1M | 73.6M | -28M | -7.4M | -30.2M | -32.7M | 33.1M | 13.4M | |
-11.8M | -11.9M | -77.6M | -77M | -76.3M | -78.4M | -82.2M | -80.6M | -76.1M | -78.4M | -81.2M | -81.4M | -70.5M | -48.4M | -36.6M | -31.2M | -29M | -27.9M | -27.1M | -27.8M | |
-20M | -2.1M | -13M | -70M | -80.4M | -144.3M | -825K | -69.6M | -71.7M | -247.2M | -164.1M | -45.7M | -140.9M | -201.5M | -67.1M | -58.5M | -21.1M | -6.1M | -71.1M | -67.5M | |
1.4M | -6.3M | 0.0 | 22M | 13.9M | 5.8M | -2.3M | 3.5M | 24.4M | 13.4M | 8.7M | 6.1M | 79.6M | 12.3M | -4.9M | 6.9M | 7.3M | 4.1M | 7.5M | 1.8M | |
-202.4M | -133.2M | 10.7M | -99.5M | -104.7M | -245.2M | -154.8M | -116.7M | -159.6M | -134.7M | -235.9M | -41.1M | -120.7M | -163.9M | -107M | -69M | -73M | -62.7M | -57.6M | -74.6M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
3.2M | -9.8M | -3.5M | -16.3M | -11.2M | 12.5M | -3M | -16.8M | 18.1M | -14.8M | -24.4M | -47.5M | -10.6M | 4.8M | -3.5M | 7.2M | 2.7M | -2.6M | 2.9M | 2.4M | |
51.7M | -69.2M | -8.7M | -74.9M | -63.1M | 67.1M | -51.3M | -39.5M | 69.2M | 67.9M | 939K | -236.7M | 205.1M | 47.1M | 42.6M | 72.3M | 43.5M | 27.3M | -34M | -34.1M | |
186.9M | 256.1M | 264.7M | 339.6M | 402.7M | 335.6M | 386.9M | 426.4M | 357.2M | 289.4M | 288.4M | 525.2M | 320M | 273M | 230.3M | 158M | 114.6M | 87.3M | 121.4M | 155.4M | |
238.6M | 186.9M | 256.1M | 264.7M | 339.6M | 402.7M | 335.6M | 386.9M | 426.4M | 357.2M | 289.4M | 288.4M | 525.2M | 320M | 273M | 230.3M | 158M | 114.6M | 87.3M | 121.4M | |
46M | 70.2M | 60.1M | 49M | 73M | 315.3M | 111.9M | 132.4M | 242.4M | 225M | 265.5M | -157.9M | 345.1M | 214.3M | 182.5M | 134.1M | 113.7M | 87.3M | 25.9M | 38.1M |
SEC Filings
NUS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 |
Related Guides
Continue your NUS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.